University College London Hospitals NHS Foundation Trust

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, November 7, 2023
MTD, University College London, US, Maxima and minima, Doctor of Philosophy, Index, Orphan, ClinicalTrials.gov, GI/GU, Clinical trial, Oncogene, University College London Hospitals NHS Foundation Trust, Cancer, Pancreatic cancer, TD2, Safety, Therapy, Patient, Oncology, Pharmaceutical industry, Q4

It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.

Key Points: 
  • It was discovered by Dr. Stephen Neidle’s team at the University College London and exclusively licensed by Qualigen in January 2021.
  • Qualigen received Orphan Drug Designation for the intended treatment of pancreatic cancer in January and clearance from the US FDA to initiate a Phase 1 clinical trial in July of this year.
  • Qualigen anticipates providing an update on safety and preliminary efficacy of the Phase 1a study in the first half of 2024.
  • For more information on QN-302 or the Phase 1a clinical trial, please visit our QN-302 clinical trial website on ClinicalTrials.gov.

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

Retrieved on: 
Tuesday, October 17, 2023
PIN, University College London, Conference call, Therapy, Webcast, ET, CAR, BST, Hospital, University College London Hospitals NHS Foundation Trust, Conference, SLE

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.

Key Points: 
  • LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will hold a virtual event on Tuesday, October 24, 2023 at 8:30 am ET, 1:30 pm BST, to discuss the company’s CAR T strategy in autoimmune diseases and recent decision to advance obecabtagene autoleucel (obe-cel) into a Phase 1 study in systemic lupus erythematosus (SLE) in early 2024.
  • The event will include an introduction from Autolus’s Chief Executive Officer, Dr Christian Itin, and presentations from key thought leader, Dr Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, and company management.
  • Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
  • A simultaneous audio webcast and replay along with presentation materials will be accessible on the events section of Autolus’s website.

12th IAU Annual Conference in 2023: London Witnesses Outstanding Gathering in the Field of Urolithiasis

Retrieved on: 
Wednesday, October 11, 2023
Conference, Quality of life, EULIS, WCE, Book, Urology, Patient, University College London Hospitals NHS Foundation Trust, BPS Barbara Wilson Lifetime Achievement Award, Guideline, Kidney, UCLH, Surgeon, European Society of Clinical Microbiology and Infectious Diseases, International Alliance of Research Universities, Minimally invasive procedure, SIU, Research, Pharmaceutical industry, Endoscopy, Kidney stone disease, IAU

From October 4th to 6th 2023, the 12th Annual Conference of IAU was grandly held in London, United Kingdom.

Key Points: 
  • From October 4th to 6th 2023, the 12th Annual Conference of IAU was grandly held in London, United Kingdom.
  • In addition to academic communication, the IAU Annual Conference presented multiple awards to recognize experts who have made outstanding contributions in the field of urolithiasis.
  • The first-ever IAU Annual Conference held in London highlighted the significant progress achieved in international collaboration in this field.
  • The 2023 IAU Annual Conference in London was a historic event in the field of urolithiasis.

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

Retrieved on: 
Tuesday, September 26, 2023
DNA, PK, Francis Crick Institute, MYC, Methylation, Therapy, Hepatocellular carcinoma, Chills, Fever, Pharmacokinetics, Omega, King's College London, Part, Messenger, University College London Hospitals NHS Foundation Trust, PIN, Patient, Cancer, Webcast, DNA methylation, LNP, FDA, HCC, Safety, Vaccine, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene. OTX-2002, the Company’s lead development candidate, is designed to pre-transcriptionally downregulate MYC, a master oncogene implicated in more than 50% of all cancers and approximately 70% of HCC cases.

Key Points: 
  • “These early clinical data are consistent with our preclinical experiments, giving us confidence that our approach has the potential to translate to anti-tumor activity and clinical benefit.
  • These preliminary data cover the first two dose cohorts from the monotherapy dose escalation portion of the trial, which is currently being conducted at clinical sites across the United States and Asia.
  • These new data, while early, are incredibly promising and highlight the potential of programmable epigenomic mRNA therapeutics to provide a groundbreaking new strategy to pre-transcriptionally control gene regulation.
  • Omega will host a webcast and conference call for analysts and investors to review these data today, Tuesday, September 26, 2023, at 8:00 a.m.

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
Thursday, August 24, 2023
University College London Hospitals NHS Foundation Trust, University College London, Cardiac magnetic resonance imaging, PALO, Calendar, European Society of Cardiology, Magnetic resonance, Congress, TTR, Patient, Division, Cancer, Heart failure, Webcast, ESC, Safety, Hospital, Medicine, Cardiology, Amyloidosis

ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).

Key Points: 
  • ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).
  • BridgeBio will host an investor call with members of the Company’s leadership team as well as Julian Gillmore, M.D., Ph.D., on Monday, August 28 at 8:30 am ET to discuss the results shared at the meeting.
  • A link to the webcast may be accessed from the event calendar page of BridgeBio’s website at https://investor.bridgebio.com/ .
  • A replay of the conference call and webcast will be archived on the Company’s website and will be available for at least 30 days following the event.

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Vaccine, Inflammation, University College London Hospitals NHS Foundation Trust, University College London, Global production network, Medicine, UCL, Inc., University, GPD, Cancer Institute, PFE, Rare disease, Cancer, Joint Planning and Development Office, Royal Marsden Hospital, Pfizer, Doctor of Philosophy, Organization, Development, Acquisition, Patient, University of Pretoria, Internal medicine, Hematology, Royal Free Hospital, Immunology, Family, NYSE, Infection, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.
  • Effective today, Chris Boshoff, M.D., PhD, will join Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla.
  • Under his leadership, Pfizer will continue to invest in its fight against cancer and Dr. Boshoff will be the single point of accountability for the entire oncology pipeline – from discovery to early and late-phase clinical development.
  • Mikael Dolsten, M.D., PhD, currently Chief Scientific Officer & President, Pfizer Worldwide Research, Development and Medical, will now expand his role to lead all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas as Chief Scientific Officer, President, Pfizer Research & Development.

Discovery Of New Genetic Biomarkers May Pave The Way For A Lab Test For Bipolar Spectrum Disorder Within Three Years

Retrieved on: 
Thursday, July 13, 2023
DSM-IV codes, Thyroid hormones, Depression, Life, KCL, National Center for Biotechnology Information, Brain, King's College London, Approximation error, Invention, University College London Hospitals NHS Foundation Trust, TLPC, Journal, Patient, Psychiatry, Medicine, Transcranial magnetic stimulation, Pharmaceutical industry

LONDON, July 13, 2023 /PRNewswire/ -- A research team from The London Psychiatry Centre (TLPC) has discovered new genetic biomarkers in bipolar spectrum disorder .

Key Points: 
  • LONDON, July 13, 2023 /PRNewswire/ -- A research team from The London Psychiatry Centre (TLPC) has discovered new genetic biomarkers in bipolar spectrum disorder .
  • This discovery may pave the way for the first ever diagnostic lab test in psychiatry.
  • It reported a surprising number of mutations occurring in bipolar spectrum disorder compared to the general population.
  • We may well be 24-36 months away from a diagnostic lab test for bipolar spectrum disorder.

Discovery Of New Genetic Biomarkers May Pave The Way For A Lab Test For Bipolar Spectrum Disorder Within Three Years

Retrieved on: 
Thursday, July 13, 2023
DSM-IV codes, Thyroid hormones, Depression, Life, KCL, National Center for Biotechnology Information, Brain, King's College London, Approximation error, Invention, University College London Hospitals NHS Foundation Trust, TLPC, Journal, Patient, Psychiatry, Medicine, Transcranial magnetic stimulation, Pharmaceutical industry

LONDON, July 13, 2023 /PRNewswire/ -- A research team from The London Psychiatry Centre (TLPC) has discovered new genetic biomarkers in bipolar spectrum disorder .

Key Points: 
  • LONDON, July 13, 2023 /PRNewswire/ -- A research team from The London Psychiatry Centre (TLPC) has discovered new genetic biomarkers in bipolar spectrum disorder .
  • This discovery may pave the way for the first ever diagnostic lab test in psychiatry.
  • It reported a surprising number of mutations occurring in bipolar spectrum disorder compared to the general population.
  • We may well be 24-36 months away from a diagnostic lab test for bipolar spectrum disorder.

First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study

Retrieved on: 
Tuesday, July 11, 2023
General Health, Health, Cardiology, Medical Devices, Heart failure, Richard M. Ross Heart Hospital, Physician, Heart, Principal investigator, MD, Patient, Division, Columbia University Vagelos College of Physicians and Surgeons, Surgeon, Weill Cornell Medicine, University College London Hospitals NHS Foundation Trust, Joe Byrd (Cherokee Nation Principal Chief), Medical device, Medicine

FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study.

Key Points: 
  • FIRE1 today announced that the first U.S. patients have been successfully implanted with its FIRE1™ System for remote heart failure monitoring in an Early Feasibility Study.
  • The study will assess FIRE1’s novel solution to improve outcomes for heart failure patients.
  • The first patient was implanted at Austin Heart, Texas, where Kunjan Bhatt, MD, leads the study as Principal Investigator and Thomas McMinn, MD, performed the implants.
  • “We are delighted to announce the first implants in the U.S. of this new, transformative technology for patients with chronic heart failure,” said Dr. Bhatt.

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Retrieved on: 
Wednesday, June 21, 2023
University College London Hospitals NHS Foundation Trust, University College London, CHDI, UCL, FRCP, Central nervous system, Natural history, Depression, DSMB, Event, TMS, AFL, Neurodegenerative disease, Clinical trial, Cure, Research, Inflammation, TFC, Interest, Data monitoring committee, CAG, Back pain, SAE, Data analysis, PIN, Patient, Composite, Deep vein thrombosis, Functional capacity evaluation, CSF, Phase, Immunosuppression, Nerve, Unified, Vaccine, Pharmaceutical industry, EU

Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.

Key Points: 
  • Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
  • Phase I/II clinical trial of AMT-130, a one-time administered investigational gene therapy for Huntington’s Disease,” stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure .
  • Phase I/II Trial of AMT-130 in Huntington’s Disease
    A total of 26 patients with early-manifest Huntington’s disease have been enrolled in the multi-center, U.S.
  • Phase I/II clinical trial concluded there are no safety concerns with either dose and recommended continuing clinical development of AMT-130.